ESMO 2024 Insights: STAMPEDE2 Trial - Stereotactic Ablative Body Radiotherapy for Newly Diagnosed Oligometastatic Prostate Cancer Starting ADT

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

10 seconds

This video is featured in the 2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: STAMPEDE2 Trial - Stereotactic Ablative Body Radiotherapy for Newly Diagnosed Oligometastatic Prostate Cancer Starting ADT

By 2024 ESMO Annual Meeting Insights Hub FEATURING Hoda Abdel-Aty

101 views

September 24, 2024

Comments 0

Hypothetical Patient Case: 1L Advanced Renal Cell Carcinoma With Mul…

Feat. R. Alter, A. Rezazadeh

Treatment Decisions When Initiating a Tyrosine Kinase Inhibitor and …

Feat. K. Hanna, J. Strauss

2024 ESMO Annual Meeting Insights Hub: GU Videos

New

ESMO 2024 Summary: Developmental Therapeutics Highlights

2024 ESMO Annual Meeting Insights Hub

G. Sonpavde

251 views

3 weeks ago

ESMO 2024 Summary: Practice-Changing Trials for Patients With Locali…

2024 ESMO Annual Meeting Insights Hub

P. Grivas

245 views

2 months ago

ESMO 2024 Summary: Important GU Trials - EV-103 5-Year Follow-Up (la…

2024 ESMO Annual Meeting Insights Hub

E. Plimack

173 views

1 month ago

View All

APCCC 2026

Fri, Feb 27, 2026

RENALC-BLADDR-PROSCA 2024

PROSCA 2024 - Hybrid Global Forum on GU Oncology

Thu, Nov 28, 2024

ASCO® GU 2024 Summary: "Important Prostate Cancer Take-Home Messages"

Insights from 2024 ASCO® GU Annual Meeting

E. Efstathiou

2.6K views

9 months ago

Recent GU Developments and Their Clinical Implications

Insights from 2024 ASCO® GU Annual Meeting

T. Powles, B. Rini

1.5K views

8 months ago

Bladder Cancer Highlights From ASCO® 2024

2024 ASCO® Annual Meeting Insights Hub

G. Sonpavde

1.4K views

5 months ago

Clinical Highlights From AACR 2024: Trials Evaluating Selected New T…

AdventHealth

G. Sonpavde

1.9K views

7 months ago

Cancer Screening Molecular Tools

Fengting Yan

2.5K views

11 months ago

Aggressive Variant Prostate Cancer: Definition, Diagnosis, Treatment…

Ana Aparicio

1.6K views

11 months ago

Hyperprogression in Cancer Treated With Immunotherapy

Northwestern Medicine Oncology and Hematology

Y. Chae

1.2K views

7 months ago

Whole-Body MRI: Past, Present, and Future

Houston Methodist

N. Gupta

1.7K views

1 year ago

Surgical Management of High-Risk and Locally Advanced Prostate Cancer

Yale Cancer Center

I. Kim

431 views

1 month ago

AUA Advanced Prostate Cancer Guidelines: 2023 Update

Robert Dreicer

1.3K views

11 months ago

ASCO® 2024 Prostate Cancer Take-Home Messages

2024 ASCO® Annual Meeting Insights Hub

E. Efstathiou

606 views

3 months ago

Testosterone Suppression and Recovery in Patients With Advanced Pros…

Benjamin L. Maughan

661 views

5 months ago

ASCO® 2024 Summary: "Prostate Cancer Highlights"

2024 ASCO® Annual Meeting Insights Hub

N. Reizine, K. Tawagi

566 views

4 months ago

ESMO 2024 Summary: GU Practice-Changing Trial Results of PEACE-3 (mC…

2024 ESMO Annual Meeting Insights Hub

R. Dreicer

276 views

1 month ago

Precision Therapies for Prostate Cancer

University of Miami Sylvester Comprehensive Cancer Center

M. Bilusic

356 views

3 months ago

GnRH Agonists vs. Antagonists in Prostate Cancer

Patrick Campbell

318 views

2 months ago

ASCO® 2024 Insights: "Evaluation of Persistence and Adherence for Or…

2024 ASCO® Annual Meeting Insights Hub

J. Hafron

643 views

5 months ago

ASCO® 2023 Insights: "PSMAddition - A Phase 3 Trial to Compare Treat…

Insights from 2023 ASCO® Annual Meeting

S. Tagawa

1.8K views

1 year ago

New

Visible vs. Invisible Cancers - The Genomics and Natural History

Laurence Klotz

178 views

2 weeks ago

Understanding PSMA PET Scans in Prostate Cancer Diagnosis

GRACE

K. Jatwani, K. Tawagi, M. Kurian

242 views

3 months ago

AUTOPLAY

Login

Login

Join VuMedi

ESMO 2024 Insights: STAMPEDE2 Trial - Stereotactic Ablative Body Radiotherapy for Newly Diagnosed Oligometastatic Prostate Cancer Starting ADT

Hypothetical Patient Case: 1L Advanced Renal Cell Carcinoma With Mul…

Treatment Decisions When Initiating a Tyrosine Kinase Inhibitor and …

2024 ESMO Annual Meeting Insights Hub: GU Videos

ESMO 2024 Summary: Developmental Therapeutics Highlights

ESMO 2024 Summary: Practice-Changing Trials for Patients With Locali…

ESMO 2024 Summary: Important GU Trials - EV-103 5-Year Follow-Up (la…

Recommended

APCCC 2026

PROSCA 2024 - Hybrid Global Forum on GU Oncology

ASCO® GU 2024 Summary: "Important Prostate Cancer Take-Home Messages"

Recent GU Developments and Their Clinical Implications

Bladder Cancer Highlights From ASCO® 2024

Clinical Highlights From AACR 2024: Trials Evaluating Selected New T…

Cancer Screening Molecular Tools

Aggressive Variant Prostate Cancer: Definition, Diagnosis, Treatment…

Hyperprogression in Cancer Treated With Immunotherapy

Whole-Body MRI: Past, Present, and Future

Surgical Management of High-Risk and Locally Advanced Prostate Cancer

AUA Advanced Prostate Cancer Guidelines: 2023 Update

ASCO® 2024 Prostate Cancer Take-Home Messages

Testosterone Suppression and Recovery in Patients With Advanced Pros…

ASCO® 2024 Summary: "Prostate Cancer Highlights"

ESMO 2024 Summary: GU Practice-Changing Trial Results of PEACE-3 (mC…

Precision Therapies for Prostate Cancer

GnRH Agonists vs. Antagonists in Prostate Cancer

ASCO® 2024 Insights: "Evaluation of Persistence and Adherence for Or…

ASCO® 2023 Insights: "PSMAddition - A Phase 3 Trial to Compare Treat…

Visible vs. Invisible Cancers - The Genomics and Natural History

Understanding PSMA PET Scans in Prostate Cancer Diagnosis